LATS2
Summary: This gene encodes a serine/threonine protein kinase belonging to the LATS tumor suppressor family. The protein localizes to centrosomes during interphase, and early and late metaphase. It interacts with the centrosomal proteins aurora-A and ajuba and is required for accumulation of gamma-tubulin and spindle formation at the onset of mitosis. It also interacts with a negative regulator of p53 and may function in a positive feedback loop with p53 that responds to cytoskeleton damage. Additionally, it can function as a co-repressor of androgen-responsive gene expression. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| large tumor suppressor kinase 2 | MIM:604861 | Ensembl:ENSG00000150457 | HGNC:HGNC:6515 | PA30302 | 13q12.11 |
GO terms in LATS2
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IBA | GO:0004674 | protein serine/threonine kinase activity |
| MF | IDA | GO:0004674 | protein serine/threonine kinase activity |
| MF | TAS | GO:0004674 | protein serine/threonine kinase activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IDA | GO:0005524 | ATP binding |
| MF | IEA | GO:0046872 | metal ion binding |
| BP | IBA | GO:0000082 | G1/S transition of mitotic cell cycle |
| BP | IDA | GO:0000082 | G1/S transition of mitotic cell cycle |
| BP | IDA | GO:0006468 | protein phosphorylation |
| BP | IDA | GO:0009755 | hormone-mediated signaling pathway |
| BP | IBA | GO:0018105 | peptidyl-serine phosphorylation |
| BP | IBA | GO:0035329 | hippo signaling |
| BP | IDA | GO:0035329 | hippo signaling |
| BP | TAS | GO:0035329 | hippo signaling |
| BP | IBA | GO:0035556 | intracellular signal transduction |
| BP | IDA | GO:0035556 | intracellular signal transduction |
| BP | IBA | GO:0043065 | positive regulation of apoptotic process |
| BP | IDA | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity |
| BP | IBA | GO:0046620 | regulation of organ growth |
| BP | IEA | GO:0051301 | cell division |
| BP | IMP | GO:0090090 | negative regulation of canonical Wnt signaling pathway |
| CC | IBA | GO:0000922 | spindle pole |
| CC | IDA | GO:0000922 | spindle pole |
| CC | IBA | GO:0005634 | nucleus |
| CC | IDA | GO:0005634 | nucleus |
| CC | NAS | GO:0005634 | nucleus |
| CC | IDA | GO:0005815 | microtubule organizing center |
| CC | IDA | GO:0005829 | cytosol |
| CC | TAS | GO:0005829 | cytosol |
Gene expression in normal tissue: LATS2
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in LATS2
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-2028269 | Signaling by Hippo |
| pid | ar_pathway | Coregulation of Androgen receptor activity |
| kegg | hsa04390 | Hippo signaling pathway - Homo sapiens (human) |
| kegg | hsa04392 | Hippo signaling pathway - multiple species - Homo sapiens (human) |
| wikipathways | WP4239 | EMT transition in Colorectal Cancer |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD484 | Pluripotin | 3 |
| iGMDRD546 | BMS-754807 | 1 |
| iGMDRD387 | CHIR-99021 | 2 |
| iGMDRD1008 | SR-II-138A | 1 |
| iGMDRD579 | PF750 | 7 |
| iGMDRD126 | Tipifarnib | 5 |
| iGMDRD433 | Lexibulin | 2 |
| iGMDRD634 | SCHEMBL2608041 | 5 |
| iGMDRD679 | Bistramide A | 3 |
| iGMDRD466 | Chaetocin | 1 |
| iGMDRD639 | YK 4-279 | 3 |
| iGMDRD193 | Fqi1 | 4 |
| iGMDRD446 | LY 2183240 | 6 |
| iGMDRD441 | TW 37 | 3 |
| iGMDRD187 | BRD9876 | 5 |
| iGMDRD802 | 4-methylfasudil | 3 |
| iGMDRD255 | SB225002 | 2 |
| iGMDRD138 | PX 12 | 1 |
| iGMDRD356 | PNU-74654 | 1 |
| iGMDRD451 | Serdemetan | 2 |
| iGMDRD64 | Parbendazole | 4 |
| iGMDRD369 | TGX-115 | 1 |
| iGMDRD60 | Quinoclamine | 5 |
| iGMDRD506 | Fedratinib | 2 |
| iGMDRD888 | Compound 44 | 1 |
| iGMDRD100 | Zebularine | 3 |
| iGMDRD399 | Selumetinib | 3 |
| iGMDRD74 | Idarubicin | 2 |
| iGMDRD523 | Cyanoquinoline, 11 | 2 |
| iGMDRD405 | PIK-75 | 1 |
| iGMDRD424 | Tamatinib | 2 |
| iGMDRD154 | NSC23766 | 5 |
| iGMDRD901 | ELCPK | 1 |
| iGMDRD123 | Isoevodiamine | 3 |
| iGMDRD351 | GW843682X | 5 |
| iGMDRD314 | Tanespimycin | 1 |
| iGMDRD341 | Triacsin c | 2 |
| iGMDRD481 | Dactolisib | 2 |
| iGMDRD77 | Itraconazole | 3 |
| iGMDRD267 | Oligomycin A | 3 |
| iGMDRD705 | Nakiterpiosin | 3 |
| iGMDRD6 | AM-580 | 5 |
| iGMDRD434 | BMS-536924 | 1 |
| iGMDRD158 | NSC141540 | 4 |
| iGMDRD121 | GMX1778 | 2 |
| iGMDRD322 | FK 866 | 2 |
| iGMDRD505 | Pevonedistat | 3 |
| iGMDRD886 | Compound 1541A | 2 |
| iGMDRD300 | Tozasertib | 2 |
| iGMDRD871 | BRD6368 | 3 |
| iGMDRD414 | MST-312 | 3 |
| iGMDRD367 | Ro 28-1675 | 5 |
| iGMDRD872 | BRD7137 | 6 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in LATS2
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.